This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Mar 2011

Biothera Launches Leukaemia Drug Study

Chronic lymphocytic leukaemia is cancer of the blood and bone marrow. It affects more than 100,000 Americans, with over 15,000 new diagnoses each year.

Biothera has initiated a Phase I/II clinical trial to evaluate Imprime PGG in combination with alemtuzumab (Campath) and rituximab (Rituxan) in patients with earlier-stage, high-risk chronic lymphocytic leukaemia.

 

Chronic lymphocytic leukaemia is cancer of the blood and bone marrow. It affects more than 100,000 Americans, with over 15,000 new diagnoses each year.

 

The Phase I, open-label, dose-escalation study will dose up to 16 patients and will determine the maximum tolerated dose of Imprime PGG in combination with alemtuzumab and rituximab.

 

The Phase II study will involve 55 patients, who will receive Imprime PGG at the dose level identified in Phase I of the study. It will evaluate the rat

Related News